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Abstract
The most recent genome-wide association study in amyotrophic lateral sclerosis (ALS) demonstrates a disproportionate
contribution from low-frequency variants to genetic susceptibility to disease. We have therefore begun Project MinE, an
international collaboration that seeks to analyze whole-genome sequence data of at least 15 000 ALS patients and 7500
controls. Here, we report on the design of Project MinE and pilot analyses of successfully sequenced 1169 ALS patients and
608 controls drawn from the Netherlands. As has become characteristic of sequencing studies, we ﬁnd an abundance of rare
genetic variation (minor allele frequency < 0.1%), the vast majority of which is absent in public datasets. Principal
component analysis reveals local geographical clustering of these variants within The Netherlands. We use the whole-
genome sequence data to explore the implications of poor geographical matching of cases and controls in a sequence-based
disease study and to investigate how ancestry-matched, externally sequenced controls can induce false positive associations.
Also, we have publicly released genome-wide minor allele counts in cases and controls, as well as results from genic burden
tests.
Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly progres-
sing, fatal neurodegenerative disease [1]. Twin studies
estimate the heritability of ALS to be ~60%, suggesting a
strong genetic component contributing to disease risk [2],
and approximately 10–15% of patients have a clear family
history of disease [3]. Genetic risk factors have been
extensively studied in familial ALS cases, and this effort
has led to the identiﬁcation of highly penetrant causal var-
iants, including variants residing in SOD1 [4], TARBP [5],
FUS [6], and C9orf72 [7, 8]. In so-called sporadic ALS
cases, who have no known family history of disease and
comprise the majority of all cases, only a small number of
other common genetic risk loci have been identiﬁed.
Among these loci are the ATXN2 CAG repeat expansion
[9], variants in C21orf2 [10], common variation within the
UNC13A [11], SARM1 [12], MOBP [10], and SCFD1 [10]
loci and, most importantly, the highly pathogenic C9orf72
repeat expansion. The latter highlights the typical categor-
ization of “familial” and “sporadic” ALS as likely non-
distinct groups with overlapping genetic architectures.
Despite these recent advances in ALS genetics, the bulk
of risk loci in ALS remain undiscovered. The most recent
and largest ALS GWAS, performed in 12,577 cases and
23,475 controls, showed a disproportionate contribution of
low-frequency variants to the overall risk of ALS [10].
Genome-wide association studies to date have focused
almost exclusively on common variation (minor allele fre-
quency (MAF) > 1%)), leaving lower-frequency and rarer
variants segregating in the general population essentially
untested. Thus, there is a pressing need to study rare var-
iation across the full length of the genome in cases with and
without family history of disease. To this end, we have
begun Project MinE, a large-scale whole-genome sequen-
cing study in ALS. The project leverages international
collaboration and recent developments in sequencing tech-
nologies, allowing us to explore the full spectrum of genetic
variation in samples collected worldwide. Project MinE
seeks to obtain sequencing data in 15,000 ALS patients and
7,500 matched controls with the aim of identifying new loci
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associated to ALS risk, ﬁne-map known and novel loci, and
provide a publicly-available summary-level dataset that will
enable further genetic research of this and other diseases. A
data access committee controls access to raw data, ensuring
a FAIR data setup (http://www.datafairport.org).
While common variant association studies have become
mostly standardized over the last decade, rare variant
association studies such as Project MinE face an array of
new challenges. Sequencing studies demand large sample
sizes to detect small effects at rare variants, thus making
large-scale collaborative consortia a necessity. Sequence
data itself, measuring into the terabytes, poses a substantive
data storage, processing, and management challenge. The
analytic effects of (tight) spatial clustering of rare variants is
not yet well understood [13, 14], making careful case/con-
trol selection and proper handling of population stratiﬁca-
tion key. Rare variant association studies typically employ
genic burden testing to overcome power problems, thus
requiring a series of analytic choices be made regarding the
functional annotation [15] and statistical analysis of the
data. Here, we discuss the “pilot phase” of Project MinE,
performed in 1,264 cases and 611 controls collected in the
Netherlands. Though the sample size is too small to detect
moderate-effect genetic associations, it allows us to explore
the implications of these many analytic challenges faced by
Project MinE or any disease study employing sequence
data, to understand the genetic basis of disease. We outline
the formation of the consortium, study design challenges,
data Quality control (QC) and analysis approaches
employed by the project, and publicly release all minor
allele counts in cases and controls together with results from
genic burden tests derived from this dataset.
Materials and methods
Consortium design
The Project MinE consortium includes ALS research groups
from 16 different countries collaborating in a “franchise”
design (www.projectmine.com, Fig. 1). This design means
that samples and sample-afﬁliated data (e.g., dense pheno-
typing) from partners are collected, processed and stored
according to the same protocol, while partners maintain full
control over their samples, afﬁliated data, and any addi-
tional data generated on those samples. Within the con-
sortium, ALS patients and controls are ascertained through
clinics afﬁliated to the research groups. At these clinics,
Fig. 1 Consortium design. Consortium structure including funding
agencies, research groups, the Project MinE general assembly, sub-
projects, and data management. Each research group obtains funding
using uniform grant proposals shared between the research groups.
DNA samples are provided to the sequencing providers via the Project
MinE general assembly. Samples are sequenced, and data is centrally
stored (the size of the data for the ﬁrst 1,935 samples is indicated in
parentheses; the full dataset for N= 22,500 samples will be ~1.7
petabytes). External data can also be contributed to and integrated into
the dataset. Different research groups, including external groups,
collaborate to work on speciﬁc projects. ALS amyotrophic lateral
sclerosis, WGS whole-genome sequencing
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neurologists obtain a standardized core clinical data set with
phenotypic information (Supplementary Table 1) and blood
is drawn for DNA isolation. DNA samples are stored on
site, but are collectively prepared for sequencing at com-
mercial sequencing providers, in batches of up to
1,000 samples, so research groups can proﬁt from a lower
pricing scheme available when large numbers of DNA
samples are provided together.
A number of variables, including pricing for varying
numbers of genomes, DNA input requirements, availability
of PCR-free library preparation, and methods for data
delivery, were all considered during selection of a sequen-
cing provider (Supplementary Table 2). The majority of the
data to date have been sequenced at Illumina (San Diego,
CA, USA); a small subset is currently being sequenced
locally in Australia and Canada. From Illumina, the data are
transferred through the internet (via a secure connection) to
SURFsara (Amsterdam, The Netherlands). After arrival, the
data is automatically checked for corruption and stored in
duplicate on two geographically separated tape silos. The
storage system is connected to a distributed parallel ﬁle
system (dCache [16]) that provides high performing ﬁle
service to a 5,600 core high-throughput computing cluster.
From here, consortium members can access the genomes
of their samples and ask that their data be additionally
backed up on the High-Performance Compute cluster at the
University Medical Center Utrecht (Utrecht, The Nether-
lands). Analysis teams (possibly including researchers from
external groups) can submit analysis proposals to the con-
sortium and then gain access to all genomes and make use
of the SURFsara compute facilities (Fig. 1). Access to the
data or usage of the compute facilities is contingent on (a)
X.509 authentication certiﬁcates and (b) proposed analyses
for the data. This data infrastructure allows, for example,
particular cohorts and individuals access to particular sub-
sets or all of the data, depending on the analysis. Based on
permission given by the manager of the data (i.e., the
principal investigator of the contributing research group),
access is provided through the gridftp protocol v2 that is
tailored for large and reliable ﬁle transfers. The X.509
certiﬁcates allow for the possibility to scale out to other
compute facilities; given valid credentials, the data can then
be accessed from anywhere.
Sample selection
Patients were diagnosed with deﬁnite, probable, and prob-
able lab-supported ALS according to the revised El Escorial
Criteria [17]. For the pilot analyses presented here, all
patients were seen by neurologists specialized in motor
neuron diseases at the University Medical Center Utrecht
and Academic Medical Center (Amsterdam, The Nether-
lands). The samples were all included in the Prospective
ALS study in the Netherlands (PAN), an incidence-based
registry of ALS cases [18]. Controls were population-based
controls that were matched for age, sex, and geographical
region. As is true for all contributing cohorts to Project
MinE, cases and controls were ascertained in a roughly 2:1
ratio; the 2:1 case-control ratio was selected to improve
detection of variants in cases and with the plan to include
publicly-available sequenced controls in future analyses.
Phenotypic information
For all participants in Project MinE, we have deﬁned a core
clinical dataset, meant to be collected and made available
for all cases (Supplementary Table 1). Phenotypic infor-
mation is stored physically separately (https://euromotor.
umcutrecht.nl) from the genetic data in a clinical database
called Progeny. The phenotypic and genetic data can be
connected through sample identiﬁers. Phenotypic data sto-
rage is organized similarly to the sequencing data: every
contributing group has default full access to their own
phenotypic data, but data can easily be jointly shared ana-
lysed if desired. This core clinical dataset includes date of
birth, sex, site of onset, date of disease onset, diagnostic
category, Forced Vital Capacity at time of diagnosis, cog-
nitive status, and a revised ALS functional rating scale score
[19]. The required endpoint data include date of death, date
of starting invasive ventilation or requiring continuous non-
invasive ventilation. For the pilot data used in this study, we
obtained additional information on place of birth through
the Dutch Municipal Personal Records Database.
Whole-genome sequencing
Venous blood was drawn from patients and controls from
which genomic DNA was isolated using standard meth-
ods. We set the DNA concentrations at 100 ng/μl as
measured by a ﬂuorometer with the PicoGreen® dsDNA
quantitation assay. DNA integrity was assessed using gel
electrophoresis. All samples were sequenced using Illu-
mina’s FastTrack services (San Diego, CA, USA) on the
Illumina HiSeq 2000 platform. Sequencing was 100 bp
paired-end performed using PCR-free library preparation,
and yielded ~40× coverage across each sample. The Isaac
pipeline [20] was used for alignment to the hg19 reference
genome as well as to call single nucleotide variants
(SNVs), insertions and deletions (indels), and larger
structural variants (SVs). Both the aligned and unaligned
reads were delivered in binary sequence alignment/map
format (BAM) together with variant call format (gVCF)
ﬁles containing the SNVs, indels and SVs [20]. gVCF
ﬁles were generated per individual and variants that failed
the Isaac-based quality ﬁlter were set to missing on an
individual basis.
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Data analysis
Quality control
QC of the data included QC at an individuals and variant
level. Full details of QC are provided in the supplement.
Principal component analysis
Principal components were calculated for all individuals
including variants at different allele frequency thresholds
using GCTA [21]. The eigenvectors of the ﬁrst twenty
principal components were regressed on latitude and long-
itude of birthplace. In a leave-one-out scheme, this linear
model was used to predict the birthplace for the individual
left out.
Identity-by-descent analysis
We phased all non-singleton variants using SHAPEIT2 [22]
and then used BEAGLE4 [23] to detect runs of identity-by-
descent (IBD) between individuals.
Association analysis
Genotypes at common variants (MAF > 0.5%) were tested for
an association with case/control status using logistic regres-
sion (PLINK v1.9) [24, 25] assuming an additive model.
Optionally, the ﬁrst ten principal components (PCs) were
included as covariates. To test rare variation, we performed
genic “burden” testing. All variants were functionally anno-
tated using ANNOVAR [26]. We then determined three
functional groups for gene-based association testing: (a) loss
of function (LOF) variants (premature stop variants, stop-loss
variants, variants at splice sites, and frameshift indels), (b)
nonsynonymous variants, and (c) LOF and nonsynonymous
variants (aggregated). Burden testing (T1, T5, Variable
Threshold, Madsen-Browning and SKAT) was implemented
using ScoreSeq [27] and performed across all variants with
MAF < 5%. All burden tests were adjusted for sex and the top
ten PCs and performed on the QC-passing set of unrelated
samples (1169 cases and 608 controls).
Population stratiﬁcation and externally sequenced controls
To assess the type I error in a burden testing framework, we
simulated 100 different phenotypes for two scenarios: per-
fect matching and imperfect matching with a North-to-
South gradient for the number of cases (keeping the case/
control counts the same, Supplementary Figure 1), and then
performed burden testing on LOF and nonsynonymous
variants with and without principal components as covari-
ates. The most extreme p-value from each simulation was
extracted (resulting in 100 extreme p-values total, per sce-
nario); the ﬁfth-most extreme p-value represented the p-
value threshold necessary to maintain study-wise type I
error at 5%. Subsequently, we assessed the impact of
including ancestry-matched, externally sequenced controls
(the Genome of the Netherlands, GoNL [14]) instead of
controls sequenced as a part of Project MinE. As their data
is mostly available formatted as VCF ﬁles, we combined
both datasets on a VCF level, without realignment or joint
variant calling. The structure of this dataset was described
by principal component analysis and we assessed inﬂation
of the test statistics when externally sequenced controls
were included in genome-wide burden testing.
Study approval and informed consent
All participants gave written informed consent and the
institutional review board of the University Medical Center
Utrecht approved this study. Additional approval was
obtained to access the Dutch Municipal Personal Records
Database.
Data access
The summary statistics generated in this study are available
at the Project MinE databrowser: http://databrowser.
projectmine.com/.
Results
Baseline characteristics and description of data
After QC, 1,169 unrelated Dutch-ancestry cases and 608
ancestrally-matched controls were available for analysis.
Their baseline characteristics are displayed in Table 1 and
the distribution of cases and controls throughout The
Netherlands is displayed in Fig. 2a. In total, 42,200,214
SNVs and indels passed QC. The majority (69%) of these
sequenced variants were rare (MAF < 0.001, <3 allele
observations in our dataset, Fig. 3). In particular, the bulk of
these rare variants were not observed in publicly available
datasets of whole-genome sequencing data including the
Genome of The Netherlands project (GoNL release 5 from
28-10-2013, N= 498) and the 1000 Genomes Project
(Phase 1 from 23-11-2010, N= 1,093). This observation
reﬂects population-speciﬁc variants and the growing num-
ber of rare variants that will continue to be discovered as
sequencing is performed in increasingly larger samples
around the globe. As expected, most common variants
(MAF > 1%) have been observed in these two datasets
(97.5% in GoNL and 98% in the 1000 Genomes Project)
reﬂecting global sharing of common variation.
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Geographic clustering
The ﬁrst and second principal components reﬂected the
geographical distribution of cases and controls in detail
(Fig. 2b). The eigenvectors of the ﬁrst principal component
explained 55% of the variance in latitude (p= 8.4 × 10−284)
and the second principal component explained 24% of the
variance in longitude (p= 1.7 × 10−107) of the geographical
distribution of the samples across the Netherlands. Predic-
tion models including the ﬁrst twenty principal components
predicted the birthplace of individuals with high accuracy
(Supplementary Figure 2). The accuracy increased when
including rarer variants; the median distance between the
predicted and actual birthplace decreased from 50 km (31
miles) when considering common variants (MAF > 0.1), to
36 km (22 miles) when including rarer variants (MAF >
0.001), illustrating the strong geographical clustering of rare
variants [28].
Sharing of IBD segments showed strong geographical
patterns throughout the Netherlands. As was observed in a
previous population genetics study in The Netherlands there
is a clear North-to-South gradient for sharing of shorter (and
thus older) IBD segments (Supplementary Figure 3a). We
also conﬁrmed the ﬁnding that people born in the Southern
provinces shared more of these IBD segments with people
from the Northern provinces than they share with people
within their own province, reﬂecting the previously
described complex migration patterns [14]. Sharing of
longer IBD segments, reﬂecting more recently shared
ancestry, was highly dependent on the distance of birth-
places between individuals (Fig. 1c, e and Supplementary
Figure 3b).
Association testing in ALS cases and controls
We found no variants reaching genome-wide signiﬁcance
(p= 5.0 × 10−8) with ALS in our sample. We looked up
known associated single-variants, three of which showed
nominal association to the trait (p < 0.05, Supplementary
Table 3). Similarly, no loci achieved exome-wide sig-
niﬁcance in burden testing (p ≈ 5.0 × 10−7, after adjusting
for 20,000 tested genes, the various burden test types, and
sets of SNPs tested; Supplementary Figure 4) due to limited
power (Supplementary Figure 5). Burden testing p-values
for all genes tested can be found at http://databrowser.
projectmine.com/.
The implications of study design
We sought to evaluate how matching cases and control,
thereby introducing ﬁne-grained population structure,
inﬂuenced the burden testing type I error rate. Therefore, we
simulated phenotypes that (1) created perfectly
geographically matched case-control sets and (2) introduced
population structure between patients and controls (Sup-
plementary Figure 1). We subsequently ran simulations that
did not correct for any covariates or those that included
common-variant (MAF > 0.1%) principal components.
Imperfect matching did not yield a markedly more stringent
p-value to maintain a study-wide type I error at 0.05 for all
burden tests (Table 2), likely due to limited power. Cor-
recting for PCs did not affect the p-value to maintain study-
wise type I error at 0.05 either.
To test the analytic implications of a study design that
uses its resources solely for the sequencing of cases and
collects controls from an external source, we merged gen-
otypes from the ALS cases with Dutch-ancestry samples
whole-genome sequenced as part of the Genome of the
Netherlands (GoNL) project [14]. Principal component
analysis indicated a clear separation of the two projects,
where PC1 effectively captured each project (Supplemen-
tary Figure 6a). Removal of highly differentiated SNPs with
a frequency difference > 5% across the two projects some-
what mitigated this separation (Supplementary Figure 6b).
As expected, single-variant testing between ALS cases and
GoNL controls revealed excessive genomic inﬂation (λ=
1.12). Similarly, burden testing comparing ALS cases and
GoNL controls revealed a strongly inﬂated QQ plot and
genomic inﬂation factor (λ= 2.49), demonstrating the
challenges of using externally sequenced controls to iden-
tify disease genes in a separately-sequenced set of cases and
controls.
Table 1 Baseline characteristics. Baseline characteristics of samples
included in Project MinE
ALS Controls
N 1,196 608
Sex, % female 41.1 43.1
Type
Familial (%) 31 (2.6) –
Sporadic (%) 1,165 (97.4) –
C9orf72
WT (%) 1,095 (91.6) –
Expanded (%) 74 (6.2) –
Unknown (%) 27 (2.3) –
Age at onset, years (IQR) 64.0 (56.6 - 70.1) –
Site of onset
Bulbar (%) 386 (32.3) –
Spinal (%) 718 (60.0) –
Thoracic (%) 30 (2.5) –
Unknown (%) 62 (5.2) –
Survival, years (IQR) 2.29 (1.58–3.28) –
Deceased (%) 966 (80.8) –
WT wild type, IQR interquartile range
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Discussion and future perspectives
Family-based and population-level genetic studies have
revealed ALS as a complex disease with a distinct role for
rarer genetic variation. Although numerous genetic variants
have been identiﬁed as conferring ALS risk, the genetic
basis in the vast majority of cases is not yet understood.
Here, we have described the design and pilot analyses of a
large-scale whole-genome sequencing study aimed at dis-
covering new genetic risk factors and further elucidating the
genetic basis of ALS.
Data sharing and transparency in scientiﬁc research is
advantageous for a host of reasons: it allows for analyses
across large sets of samples, particularly for lower-
prevalence diseases such as ALS; ensures rigorous
experiments that can be reproduced by external groups; and
allows for publicly-funded research to be made available to
the public itself. Project MinE cannot publicly release
individual-level genotype data due to consent. However,
genotype frequency information and genic burden testing
results are publicly available at the project’s online browser
(http://databrowser.projectmine.com/). This browser will be
continuously updated as the project expands, and will pro-
vide more detailed data integration in future releases. To
further enhance the transparency within the consortium
itself and with external collaborators and researchers, the
project has begun a GitHub repository, to share and main-
tain scripts and data processing pipelines.
Given the relatively low prevalence of ALS, international
collaboration is crucial to assembling large samples. Thus
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Fig. 2 Population structure by principal component and IBD analysis.
a Birthplaces of cases and controls for individuals born in The
Netherlands. b The ﬁrst two principal components reﬂect the geo-
graphical distribution of samples. c–e Relation between birthplace
distance between pairs of individuals and shared IBD segments 1–2
cM (c), 2–7 cM (d) and 7–15 cM (e). PC principal component, MAF
minor allele frequency, IBD identity by descent, km kilometer, cM
centimorgan
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far, the “franchise” design of our consortium has allowed us
to rapidly expand to sixteen participating research groups
globally. This joint effort has collected enough resources to
sequence > 7000 samples, with more currently being col-
lected. Ongoing analyses include case-control association
testing, as well as association testing in age-of-onset, and
survival time. Additionally, the available core clinical
dataset, uniformly collected for all individuals included in
Project MinE, will allow for a host of other discovery
analyses.
The pilot analyses, though small in sample size, yield
several immediate and important conclusions. First, while
genotype-called data (in VCF format) is easily handled by a
high-performance compute cluster, whole-genome BAM
ﬁles (approximately 80 gigabytes per genome) demand a
compute infrastructure that can handle terabytes and even
petabytes of data. This includes direct delivery of the gen-
omes that are currently being sequenced via a direct high-
speed connection between the sequencing provider and a
computer cluster with a GRID architecture (SURFsara).
Though some research institutions are already prepared for
such a deluge of data, others will need to carefully consider
compute infrastructure and the technical ramiﬁcations of
assembling big data before embarking on large-scale
sequencing analyses. Further, having all data stored in a
single location enables analysis across the full dataset,
including on BAM-level data.
Second, initial QC of the data suggests that the high-
depth sequencing and downstream genotype calling is
yielding high-quality data, reﬂected in our ability to
reconstruct, through principal component analysis and
identity-by-descent analyses, demographic observations that
have been made in separate large-scale sequencing efforts in
the Dutch population [14]. Further, the population analyses
performed here and in particular the birthplace analysis,
highlights the sensitivity of genome-wide sequence data.
The data must be carefully protected such that those who
have donated DNA to enable disease research, will also
remain anonymous (in accordance with the consent pro-
vided) [29].
Third, the high-resolution geographical clustering of rare
variants as observed in these analyses could pose challenges
in ﬁnding rare variants that contribute to ALS risk. The
commonly applied burden test approach, however, does not
seem to suffer from increased type I error rates induced by
modest imperfections in geographically matching samples,
as was shown by the burden test simulations. While it is
possible that aggregating rare variants (found in potentially
many geographic locations) in these tests makes the
approach more robust to population structure, these results
should be interpreted with caution. The modest power in
our pilot sample likely limited our ability to detect the
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Table 2 Population structure
and type I error. No marked
differences were observed
between the p-values in perfect
or imperfect matching scenarios
(with or without PCs) to
maintain the study-wise type I
error rate at 0.05
Scenario 1: perfect matching
Type I error in burden tests
T1 MB VT SKAT
No PCs 4.25 × 10−6 3.38 × 10−6 3.94 × 10−6 2.35 × 10−6
Common PCs 2.86 × 10−6 3.99 × 10−6 8.12 × 10−6 2.24 × 10−6
Scenario 2: imperfect matching
Type I error in burden tests
T1 MB VT SKAT
No PCs 4.40 × 10−6 1.90 × 10−5 1.46 × 10−5 6.72 × 10−6
Common PCs 5.35 × 10−6 9.35 × 10−6 1.04 × 10−9 7.81 × 10−6
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increasing type I error rates induced by imperfect geo-
graphic sample matching. With the increasing number of
ancestrally diverse samples that are being included in Pro-
ject MinE, false positive associations due to population
stratiﬁcation remain a serious concern, especially when our
aim becomes identifying the causal single variant(s) that
drive the genic burden signal. Correcting for principal
components can help to control type I error, though
potentially not sufﬁciently so in burden testing. More
sophisticated analytic approaches, such as employing a
linear mixed model in single variant and genic burden
testing, will likely be helpful in controlling for population
stratiﬁcation across the full set of Project MinE
samples [30].
We further demonstrate that inclusion of externally-
sequenced samples can pose analytical challenges. Speciﬁ-
cally, we show that using ancestry-matched controls from
publicly-available datasets can strongly inﬂate association
test statistics if the data is simply combined at VCF-level.
Sequence data can contain underlying structure due to
sequencing platforms, coverage, alignment and calling
algorithms. Inclusion of externally sequenced cases and
controls (sequenced either separately or together) is non-
trivial must be approached with extreme rigor. Methods for
handling the merging and calling of heterogeneous
sequencing datasets at a BAM-level are currently being
applied in large consortia [31–33] and indicate that
obtaining a high-quality dataset requires calling genotypes
from petabytes of raw data in a uniform way across the full
set of samples. Additional developments in handling het-
erogeneous sequence data include association testing on
read-level data to allow for externally sequenced controls
[34]. Although these methods come with signiﬁcant com-
putational burden, similar approaches could be applied in
Project MinE, in an effort to expand beyond the
22,500 samples sequenced initially by the project.
With the veritable explosion in methods and approaches
being developed for whole-genome sequence data analysis,
Project MinE will seek to leverage new and powerful
methods for uncovering ALS risk variants. Current plans
include more sophisticated functional annotation techni-
ques, such as unsupervised-learning approaches to dis-
criminate between functionally relevant and benign
variation in the genome [35, 36]; implementing a linear
mixed model approach to burden testing [30]; a burden
testing framework that will focus not only on genes but also
on regulatory and other non-coding elements; and analyses
that investigate both variation and methylation data. We
have additionally established a pipeline to lift all our data to
the newest genome build (hg38), which will likely yield
better coverage of the genome in our samples. As the size of
the data expands and additional collaborators join the effort,
we will explore additional data structures that can facilitate
transcontinental data analysis with minimal physical
movement of data.
Finally, in addition to testing SNVs and indels, we will
explore the role of more complex genetic variation such as
structural variants and repeat expansions, which are known
to play an important role in ALS susceptibility, yet have
never been studied at genome-wide scale. With a global
collaboration in place, a wealth of genetic variation being
generated, and new methods for sequence data constantly in
development, Project MinE will be the largest and most
complete study of ALS genetics to date, poised to reveal
novel risk loci, ﬁne-map known disease genes, and shed
light on the biological drivers of disease.
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